Navigation Links
Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2

Alteon Inc. announced today that it has dosed its first patient in a 60-patient Phase 2 clinical trial (Study 201) of ALT-2074, its lead glutathione peroxidase mimetic, in diabetic patients with a variant of haptoglobin that renders them at high risk for cardiovascular complications.

This dose escalating study is designed to evaluate ALT-2074's ability to lower inflammatory cardiovascular biomarkers in patients with an elevated risk for cardiovascular events.

It builds on positive data from previous cardiovascular animal studies. ALT- 2074's activity in prior clinical trials demonstrated its safety and ability to lower inflammatory markers in ulcerative colitis.

'The initiation of Study 201 is a key milestone in our program for the development of ALT-2074 as a treatment for diabetic patients with a high risk of cardiovascular events,'said Malcolm W. MacNab, M.D., Ph.D., Alteon's Vice President, Clinical Development.

'We are enthusiastic about the potential that ALT-2074 has demonstrated in our preclinical models and we are aggressively pursuing clinical development in this indication.'

Diabetes and Metabolic Syndrome, diseases linked to obesity and increased oxidative stress, are growing in epidemic proportions in the United States and many other developed countries.

The major complications associated with these diseases are cardiovascular in nature, and lead to such events as stroke, heart attack, kidney failure and death. Not all patients with diabetes, however, experience these complications.

Several multinational studies have demonstrated that the increased risk of cardiovascular disease attributed to diabetes is more aptly attributed to the development of diabetes 'on top of' a predisposing genetic factor called Haptoglobin 2-2 (Hp2-2), which is found in 40% of the human population.

The combination of diabetes and Hp2-2 increases the susceptibil
'"/>




Page: 1 2

Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
6. SARS-Free Taiwan to Mark End Phase of Global Fight
7. Spray on contraceptive clears Phase I trial
8. Phase 3 trials of two multi-kinase inhibitors against cancer
9. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
10. Phase II trails of new HIV vaccine to be held in South Africa
11. FDA approves Phase 0 trial which tests experimental drugs on humans
Post Your Comments:
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
(Date:12/4/2009)Whether the H1N1 virus will come back during winter isn,t known, CDC says, , , FRIDAY, Dec. 4 (HealthDay News) -- The number of states reporting widespread swine flu activity continued to decl
Breaking Medicine News(10 mins):Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Are angry women more like men? 2Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:Swine Flu Continues to Wane 2
... a.m. ET -, EMERYVILLE, Calif., Feb. 11 Neurobio... ) today announced financial,results for its fisca...2007., Revenues for the second quarter of 2007 we...Dec. 31, 2007 versus,$5.7 million in the same peri...
...wo Little Hands Productions --,creators of the pop...ision,show designed to teach babies, toddlers and ...Language (ASL) -- will debut its second season at ... series two will continue building children,s ASL,...
...ew Solution to Increase Customer Revenues, Manage ...SE: MSY.L), the global application software and se...istan has gone live with Misys,Equation. The solut...th the bank,s 2008 strategy focused on sustaining ...
... Irvine Hires Agency for Public Relations, MISSIO...,today announces it now provides public relations ...gan in December 2007 on Web site mapping and,messa... the past year, and we,anticipate many more change...
...1 Kay Renz Public Relations,has been retained by ...ts,Peter G. Ballas MD, who has a thriving practice...highly regarded nationally as one of the foremost,...ducts. He is currently introducing Artefill (R), t...
...tes Dblur,s Software Lens(TM) Technology Into its ...YA, Israel, February 11 Dblur, the developer of,S...ategic cooperation with,STMicroelectronics (NYSE: ...The product portfolio should include a 3.2Mp, 1.75...
Other Medicine News:Health News:Neurobiological Technologies Reports Second Quarter Financial Results 2Health News:Neurobiological Technologies Reports Second Quarter Financial Results 3Health News:Neurobiological Technologies Reports Second Quarter Financial Results 4Health News:Neurobiological Technologies Reports Second Quarter Financial Results 5Health News:Two Little Hands Productions, Creators of Popular Children's TV Series Signing Time, Debuts Second Season at This Year's Toy Fair 2008 2Health News:Mybank Goes Live With Misys Equation to Support Rapid Growth and Meet Future Regulatory Requirements 2Health News:St. Conti Communications to Help Adjust Chiropractor Messaging and Communications 2Health News:Leading Cosmetic Dermatologist, Peter G. Ballas II MD, Retains Kay Renz Public Relations to Promote his Practice and New Skincare Line 2Health News:Dblur Concludes Licensing Deal With STMicroelectronics 2
(Date:12/4/2009)STREAMWOOD, Ill., Dec. 4 Shared Imaging, LLC, an independent provider of CT, MRI and PET/CT systems and service programs for hospitals and healthcare providers, is excited to announce it has received
(Date:12/4/2009)WASHINGTON, Dec. 4 Chemistry World recently highlighted a new report published by the Pharmaceutical Research and Manufacturers of America ( PhRMA ) that identifies 97 new drugs and vaccines in
(Date:12/4/2009)Opposes use of imported drugs often stored in tin cans and car trunks ,, WASHINGTON, Dec. 4 Today, the senior advocacy group RetireSafe urged the Senate to defeat the Dorgan Importation plan encomp
Breaking Medicine Technology:Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgan's Drug Importation Plan Puts Seniors at Risk 2ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 1ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 2ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 3ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomyc 53677 4The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 1The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 2The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 3The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 4The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 5The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 6The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 7The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 8The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 9The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 10The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 11The Advisory Board Company Reports Fiscal Year 2010 First Quarter Results 53674 12Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 1Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 2Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 3Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 4Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 5Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 6Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 7Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 8Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 9Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 10Amgen and Wyeth Statement on FDA Announcement About Tumor Necrosis Factor 28TNF 29 Blockers 53670 11
...S, Oct. 26 The complex cases performed,during thi... Therapeutics,symposium by Dr. Tony Das, an interv...Dallas, represent the latest treatments for periph... the U.S. population ages and more,Americans live ... will also,dramatically increase the number of peo...
...SLEY, Mass., Oct. 26 Coley,Pharmaceutical Group, ...mpany,has received a $3.0 million milestone paymen...nitiation of GSK,s Phase III clinical trial in,non...eutic cancer vaccine,containing Coley,s VaxImmune(... the launch of the largest Phase III,clinical tria...
Other Medicine Technology:Cardiologists Tackle 'Next Frontier' in Cardiovascular Disease 2Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 2Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline 3
High Lite Convertible
High Lite Classic
High Beam Classic
...nalyzer is a semi-automated benchtop instrument fo...nQuick is designed to analyze and generate results...k 8+ urine test strips. The UrinQuick analyzes the...y. Test results are available in conventional, S.I...
Medicine Products: